In the Research Letter titled “Five Years of Cancer Drug Approvals: Innovation Efficacy and Costs” published online in the April 2, 2015, issue of JAMA Oncology (doi:10.1001/jamaoncol.2015.0373), an incorrect indication was listed for ibrutinib in the Table. The correct indication is mantle cell lymphoma. This article was corrected online.
Error in Table Text. JAMA Oncol. 2015;1(4):544. doi:10.1001/jamaoncol.2015.1424